IRON earnings analysis
What we found in IRON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Disc Medicine reported a significant net loss of $63.5 million for Q1 2026, highlighting a continued upward trend in operating losses compared to the previous year. The company ended the quarter with a strong cash position of $730.2 million, allowing for operational stability into 2029 despite ongoing high R&D expenditures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 2026 Net Loss Widens to $63.5M
- The company reported a net loss of $63.5 million, up $29.4 million from Q1 2025's loss of $34.1 million.
- R&D Expenses Increased 65% Year-over-Year
- Q1 R&D expenses totaled $45.9 million, a significant increase from $27.8 million in Q1 2025.
- Cash Position Remains Strong
- Ending cash, cash equivalents, and marketable securities stood at $730.2 million.
- Management Optimistic Despite Losses
- Management believes current cash resources will sustain operations into 2029.
- Investments in New Trials
- Initiatives include the AVENGER and APOLLO trials, aiming for faster regulatory pathways.
- Orphan Drug Designation Received
- Bitopertin received orphan drug designation, enhancing its market position for rare diseases.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Operating Losses
- Continued high operating losses could jeopardize future funding and operational growth.
- Regulatory Approval Uncertainty
- Bitopertin's recent CRL from the FDA raises concerns about future approvals and timelines.
- Dependence on Third-Party Suppliers
- Reliance on third-party contractors for clinical trials presents risks if they fail to comply with regulations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.69
What they said about what is next.
Outlook deferred to earnings press release / call. The company expects ongoing losses until successful product approvals.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Disc Medicine is a clinical‑stage hematology-focused biotech advancing three clinical programs (bitopertin, DISC-0974, DISC-3405) and preclinical DISC-0998. The company submitted an NDA for bitopertin (accepted Nov…
- 10-Q · November 6, 2025
- Disc Medicine reported a materially wider quarterly loss: net loss of $62,321,000 (net loss per share $1.77) for the three months ended September 30, 2025 versus $26,599,000 (net loss per share $0.89) in the year-ago…
- 10-Q · August 8, 2024
- Disc Medicine reported a Q2 net loss of $26.4M (GAAP net loss per share $1.03) as R&D and G&A increased, while completing a registered direct offering that, together with cash and marketable securities, leaves the…
- 10-Q · May 6, 2022
- Gemini Therapeutics reported a narrower first-quarter loss with operating expenses down to $15,177 thousand and net loss improving to $15,231 thousand (EPS $(0.35)) for the three months ended March 31, 2022 versus…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever